Labcorp Holdings Inc Revenue Growth Rates (LH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Labcorp Holdings Inc   (NYSE: LH)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

LH's Revenue Growth by Quarter and Year

Labcorp Holdings Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LH Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 3,731.10
1st Quarter March 3,537.60
FY 7,268.70

LHs Annual Revenue
Labcorp Holdings Inc 's Revenue in the fiscal year 2025 $ 13,951.70 millions
Labcorp Holdings Inc 's Revenue in the fiscal year 2024 $ 13,008.90 millions
Labcorp Holdings Inc 's Revenue in the fiscal year 2023 $ 12,161.60 millions
Labcorp Holdings Inc 's Revenue in the fiscal year 2021 $ 14,876.80 millions
Labcorp Holdings Inc 's Revenue in the fiscal year 2020 $ 13,978.50 millions




LH Revenue second quarter 2026 Y/Y Growth Comment
Labcorp Holdings Inc reported Revenue growth of 5.78% year on year in the second quarter 2026, to $ 3,731.10 millions, this is lower than Labcorp Holdings Inc 's recent average Revenue growth of 8.07%.

Looking into second quarter 2026 results within Medical Laboratories industry 22 other companies have achieved higher Revenue growth. While Labcorp Holdings Inc ' s Revenue increase of 5.78% ranks overall at the positon no. 2380 in the second quarter 2026.


LH Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 5.6 % 45.19 % -37.59 %
3rd Quarter September - 8.58 % 7.37 % 6.63 %
2nd Quarter June 5.78 % 9.51 % 6.17 % 3.79 %
1st Quarter March 5.75 % 5.3 % 4.57 % -22.1 %
FY   - 7.25 % 13.9 % -

Financial Statements
Labcorp Holdings Inc 's second quarter 2026 Revenue $ 3,731.10 millions LH's Income Statement
Labcorp Holdings Inc 's second quarter 2025 Revenue $ 3,527.30 millions Quarterly LH's Income Statement


LH Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -1.34 % 1.44 % -24.98 %
3rd Quarter September - 1.03 % 1.9 % 0.76 %
2nd Quarter June 5.47 % 5.45 % 1.39 % -0.13 %
1st Quarter March 0.62 % 0.47 % 38.52 % -17.32 %
FY (Year on Year)   - 7.25 % 13.9 % -


Back to LH Growth rate Comparisons >> Back to LH Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #23
Healthcare Sector #342
Overall #2380

Revenue Y/Y Growth Statistics
High Average Low
44.32 % 8.07 % -21.65 %
(Mar 31 2016)   (Mar 31 2024)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #23
Healthcare Sector #342
Overall #2380
Revenue Y/Y Growth Statistics
High Average Low
44.32 % 8.07 % -21.65 %
(Mar 31 2016)   (Mar 31 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Labcorp Holdings Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
329.52 % 4.96 % -75.3 %
(Mar 31 2016)  


LH's II. Quarter Q/Q Revenue Comment
Labcorp Holdings Inc achieved in the II. Quarter 2026 above company average sequential Revenue increase of 5.47%, to $ 3,731.10 millions, from $3,537.60 millions in the first quarter.
LH is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Laboratories industry 9 other companies have achieved higher Revenue quarter on quarter growth. While Labcorp Holdings Inc 's Revenue growth quarter on quarter, overall rank is 1122.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #10
Healthcare Sector #162
Overall #1122
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #10
Healthcare Sector #162
Overall #1122
Revenue Q/Q Growth Statistics
High Average Low
329.52 % 4.96 % -75.3 %
(Mar 31 2016)  


LH's II. Quarter Q/Q Revenue Comment
Labcorp Holdings Inc achieved in the II. Quarter 2026 above company average sequential Revenue increase of 5.47%, to $ 3,731.10 millions, from $3,537.60 millions in the first quarter.
LH is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Laboratories industry 9 other companies have achieved higher Revenue quarter on quarter growth. While Labcorp Holdings Inc 's Revenue growth quarter on quarter, overall rank is 1122.


Labcorp Holdings Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 14,348.00 $ 14,144.20 $ 13,951.70 $ 13,765.30 $ 13,483.80
Y / Y Revenue Growth (TTM) 6.41 % 7.34 % 7.25 % 14.97 % 14.78 %
Year on Year Revenue Growth Overall Ranking # 1127 # 324 # 984 # 1897 # 2047
Seqeuential Revenue Change (TTM) 1.44 % 1.38 % 1.35 % 2.09 % 2.33 %
Seq. Revenue Growth (TTM) Overall Ranking # 2380 # 895 # 848 # 1331 # 1375


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Labcorp Holdings Inc 's cumulative twelve months Revenue were $ 14,348 millions, company would post below average annual Revenue growth of 2.33% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Labcorp Holdings Inc 's Revenue growth from the 3537.6% growth in Mar 31 2026.

In the Healthcare sector 208 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 324 to 1127.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 209
Overall # 1127

Revenue TTM Y/Y Growth Statistics
High Average Low
44.32 %
 8.07 %
-21.65 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 342
S&P 500 # 2380
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Labcorp Holdings Inc 's cumulative twelve months Revenue were $ 14,348 millions, company would post below average annual Revenue growth of -21.65% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Labcorp Holdings Inc 's Revenue growth from the 3537.6% growth in Mar 31 2026.

In the Healthcare sector 208 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 324 to 1127.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 209
Overall # 1127

Revenue TTM Y/Y Growth Statistics
High Average Low
44.32 %
8.07 %
-21.65 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 342
S&P 500 # 2380




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LH's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Concentra Group Holdings Parent Inc 10.03%$ 10.030 millions
Lemaitre Vascular Inc 10.02%$ 10.017 millions
Amneal Pharmaceuticals Inc 9.93%$ 9.934 millions
Merit Medical Systems Inc9.79%$ 9.792 millions
Idexx Laboratories Inc9.73%$ 9.728 millions
Lenz Therapeutics Inc 9.72%$ 9.720 millions
Encompass Health Corporation9.58%$ 9.584 millions
Trisalus Life Sciences Inc 9.57%$ 9.567 millions
Amgen Inc 9.53%$ 9.533 millions
Sotera Health Company9.45%$ 9.452 millions
Illumina Inc 9.44%$ 9.443 millions
Stryker Corp9.42%$ 9.415 millions
International Stem Cell Corporation9.32%$ 9.318 millions
Cytosorbents Corporation9.29%$ 9.292 millions
Resmed Inc 9.22%$ 9.222 millions
Fate Therapeutics Inc 9.18%$ 9.177 millions
Bausch and Lomb Corp9.08%$ 9.077 millions
Pacs Group Inc 9.07%$ 9.071 millions
Electromed Inc 8.97%$ 8.968 millions
National Healthcare Corp8.83%$ 8.833 millions
Chemed Corporation8.80%$ 8.800 millions
Tactile Systems Technology Inc 8.76%$ 8.763 millions
Gyre Therapeutics Inc 8.72%$ 8.718 millions
P3 Health Partners Inc 8.60%$ 8.599 millions
Maravai Lifesciences Holdings Inc 8.53%$ 8.534 millions
U S Physical Therapy Inc8.47%$ 8.470 millions
Ocugen Inc 8.38%$ 8.376 millions
Baxter International Inc 8.36%$ 8.363 millions
Carlisle Companies Incorporated8.33%$ 8.334 millions
Universal Health Services Inc 8.27%$ 8.268 millions


About Labcorp Holdings Inc Revenue Growth Rates (LH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Labcorp Holdings Inc (CIK 920148).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000920148-26-000175
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Labcorp Holdings Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.